Article
The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design.
Gut - 1 Jan 2016
von Delft Annette, Humphreys Isla S, Brown Anthony, Pfafferott Katja, Lucas Michaela, Klenerman Paul, Lauer Georg M, Cox Andrea L, Gaudieri Silvana, Barnes Eleanor
Abstract excerpt
OBJECTIVE: Developing a vaccine that is cross-reactive between HCV genotypes requires data on T cell antigenic targets that extends beyond genotype-1. We characterised T cell immune responses against HCV genotype-3, the most common infecting genotype in the UK and Asia, and assessed within genotype and between genotype cross-reactivity. DESIGN: T cell targets were identified in 140 subjects with either acute,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.